Merck Gets FDA Fast Track for Efinopegdutide, Previews NASH Data Versus Novo’s Semaglutide

cafead

Administrator
Staff member
  • cafead   Jun 14, 2023 at 10:12: AM
via Monday, Merck announced that its GLP-1/glucagon receptor co-agonist efinopegdutide had won the FDA’s Fast Track designation for treating non-alcoholic steatohepatitis.

article source